Adial Pharmaceuticals announced on October 17, 2024, that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent. This patent expands the company’s intellectual property coverage for its proprietary genetic diagnostic.
The patent covers a broader range of genotype combinations identified by the genetic diagnostic for the targeted treatment of alcohol use disorder (AUD) with AD04. These combinations include the HTR3A, HTR3B, and SLC6A4 receptor sites, which are central to Adial's precision medicine approach.
This allowance is a crucial step in protecting AD04 and its use in personalized medicine, strengthening the company's market position. It provides greater flexibility and protection as Adial advances AD04 toward potential commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.